Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury.

Angiotensin II Dipeptidyl peptidase 3 Renin–angiotensin system Sepsis Shock Vasopressors

Journal

Intensive care medicine experimental
ISSN: 2197-425X
Titre abrégé: Intensive Care Med Exp
Pays: Germany
ID NLM: 101645149

Informations de publication

Date de publication:
07 Jun 2024
Historique:
received: 22 04 2024
accepted: 29 05 2024
medline: 8 6 2024
pubmed: 8 6 2024
entrez: 7 6 2024
Statut: epublish

Résumé

Dipeptidyl peptidase 3 (DPP3) is a ubiquitous cytosolic enzyme released into the bloodstream after tissue injury, that can degrade angiotensin II. High concentrations of circulating DPP3 (cDPP3) have been associated with worse outcomes during sepsis. The aim of this study was to assess the effect of Procizumab (PCZ), a monoclonal antibody that neutralizes cDPP3, in an experimental model of septic shock. In this randomized, open-label, controlled study, 16 anesthetized and mechanically ventilated pigs with peritonitis were randomized to receive PCZ or standard treatment when the mean arterial pressure (MAP) dropped below 50 mmHg. Resuscitation with fluids, antimicrobial therapy, peritoneal lavage, and norepinephrine was initiated one hour later to maintain MAP between 65-75 mmHg for 12 h. Hemodynamic variables, tissue oxygenation indices, and measures of organ failure and myocardial injury were collected. Organ blood flow was assessed using isotopic assessment ( PCZ-treated animals had reduced cDPP3 levels and required less norepinephrine and fluid than septic control animals for similar organ perfusion and regional blood flow. PCZ-treated animals had less myocardial injury, and higher PaO In an experimental model of septic shock, PCZ administration was associated with reduced fluid and catecholamine requirements, less myocardial injury and cardiovascular inflammation, along with preserved angiotensin II signaling.

Sections du résumé

BACKGROUND BACKGROUND
Dipeptidyl peptidase 3 (DPP3) is a ubiquitous cytosolic enzyme released into the bloodstream after tissue injury, that can degrade angiotensin II. High concentrations of circulating DPP3 (cDPP3) have been associated with worse outcomes during sepsis. The aim of this study was to assess the effect of Procizumab (PCZ), a monoclonal antibody that neutralizes cDPP3, in an experimental model of septic shock.
METHODS METHODS
In this randomized, open-label, controlled study, 16 anesthetized and mechanically ventilated pigs with peritonitis were randomized to receive PCZ or standard treatment when the mean arterial pressure (MAP) dropped below 50 mmHg. Resuscitation with fluids, antimicrobial therapy, peritoneal lavage, and norepinephrine was initiated one hour later to maintain MAP between 65-75 mmHg for 12 h. Hemodynamic variables, tissue oxygenation indices, and measures of organ failure and myocardial injury were collected. Organ blood flow was assessed using isotopic assessment (
RESULTS RESULTS
PCZ-treated animals had reduced cDPP3 levels and required less norepinephrine and fluid than septic control animals for similar organ perfusion and regional blood flow. PCZ-treated animals had less myocardial injury, and higher PaO
CONCLUSIONS CONCLUSIONS
In an experimental model of septic shock, PCZ administration was associated with reduced fluid and catecholamine requirements, less myocardial injury and cardiovascular inflammation, along with preserved angiotensin II signaling.

Identifiants

pubmed: 38849640
doi: 10.1186/s40635-024-00638-3
pii: 10.1186/s40635-024-00638-3
doi:

Types de publication

Journal Article

Langues

eng

Pagination

53

Informations de copyright

© 2024. The Author(s).

Références

Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801–810. https://doi.org/10.1001/jama.2016.0287
doi: 10.1001/jama.2016.0287 pubmed: 26903338 pmcid: 4968574
Vincent J-L, Jones G, David S et al (2019) Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care 23:196. https://doi.org/10.1186/s13054-019-2478-6
doi: 10.1186/s13054-019-2478-6 pubmed: 31151462 pmcid: 6545004
Rudd KE, Johnson SC, Agesa KM et al (2020) Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet 395:200–211. https://doi.org/10.1016/s0140-6736(19)32989-7
doi: 10.1016/s0140-6736(19)32989-7 pubmed: 31954465 pmcid: 6970225
Peti-Peterdi J, Harris RC (2010) Macula densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol 21:1093–1096. https://doi.org/10.1681/asn.2009070759
doi: 10.1681/asn.2009070759 pubmed: 20360309
Gleeson PJ, Crippa IA, Mongkolpun W et al (2019) Renin as a marker of tissue-perfusion and prognosis in critically ill patients*. Crit Care Med 47:152–158. https://doi.org/10.1097/ccm.0000000000003544
doi: 10.1097/ccm.0000000000003544 pubmed: 30653055
Chawla LS, Chen S, Bellomo R, Tidmarsh GF (2018) Angiotensin converting enzyme defects in shock: implications for future therapy. Crit Care 22:274. https://doi.org/10.1186/s13054-018-2202-y
doi: 10.1186/s13054-018-2202-y pubmed: 30368243 pmcid: 6204272
Bellomo R, Wunderink RG, Szerlip H et al (2020) Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care 24:43. https://doi.org/10.1186/s13054-020-2733-x
doi: 10.1186/s13054-020-2733-x pubmed: 32028998 pmcid: 7006163
Bellomo R, Forni LG, Busse LW et al (2020) Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. a clinical trial. Am J Respir Crit Care Med 202:1253–1261. https://doi.org/10.1164/rccm.201911-2172oc
doi: 10.1164/rccm.201911-2172oc pubmed: 32609011 pmcid: 7605187
Leisman DE, Fernandes TD, Bijol V et al (2020) Impaired angiotensin II type 1 receptor signaling contributes to sepsis induced acute kidney injury. Kidney Int. https://doi.org/10.1016/j.kint.2020.07.047
doi: 10.1016/j.kint.2020.07.047 pubmed: 32882263 pmcid: 8030124
Bucher M, Ittner K-P, Hobbhahn J et al (2001) Downregulation of angiotensin II type 1 receptors during sepsis. Hypertension 38:177–182. https://doi.org/10.1161/01.hyp.38.2.177
doi: 10.1161/01.hyp.38.2.177 pubmed: 11509472
Chawla LS, Bellomo R (2020) Reply to: alteration of the renin-angiotensin-aldosterone system in shock: role of the dipeptidyl peptidase 3. Am J Respir Crit Care Med. https://doi.org/10.1164/rccm.202010-3968le
doi: 10.1164/rccm.202010-3968le pubmed: 32609011 pmcid: 7605192
Picod A, Deniau B, Ayar PV et al (2020) Alteration of the renin-angiotensin-aldosterone system in shock: role of the dipeptidyl peptidase 3. Am J Respir Crit Care Med. https://doi.org/10.1164/rccm.202010-3873le
doi: 10.1164/rccm.202010-3873le
Gerard L, Lecocq M, Bouzin C et al (2021) Increased angiotensin-converting enzyme 2 and loss of alveolar type II cells in COVID-19–related acute respiratory distress syndrome. Am J Respir Crit Care Med 204:1024–1034. https://doi.org/10.1164/rccm.202012-4461oc
doi: 10.1164/rccm.202012-4461oc pubmed: 34449302 pmcid: 8663012
Jha S, Taschler U, Domenig O et al (2020) Dipeptidyl peptidase 3 modulates the renin–angiotensin system in mice. J Biol Chem 295:13711–13723. https://doi.org/10.1074/jbc.ra120.014183
doi: 10.1074/jbc.ra120.014183 pubmed: 32546481 pmcid: 7535908
Picod A, Genest M, Assad N et al (2022) Circulating dipeptidyl peptidase 3 modulates hemodynamics and the renin-angiotensin-aldosterone system in mice. Archives Cardiovasc Dis Suppl 14:185. https://doi.org/10.1016/j.acvdsp.2022.04.067
doi: 10.1016/j.acvdsp.2022.04.067
Rehfeld L, Funk E, Jha S et al (2019) Novel methods for the quantification of dipeptidyl peptidase 3 (DPP3) concentration and activity in human blood samples. J Appl Lab Med 3:943–953. https://doi.org/10.1373/jalm.2018.027995
doi: 10.1373/jalm.2018.027995 pubmed: 31639686
Lier D, Kox M, Pickkers P (2021) Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3. J Intern Med 289:792–806. https://doi.org/10.1111/joim.13220
doi: 10.1111/joim.13220 pubmed: 33381880
Blet A, Deniau B, Santos K et al (2021) Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. Crit Care 25:61. https://doi.org/10.1186/s13054-021-03471-2
doi: 10.1186/s13054-021-03471-2 pubmed: 33588925 pmcid: 7885215
Deniau B, Picod A, Lier DV et al (2021) High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the international, prospective and observational FROG-ICU cohort. Brit J Anaesth. https://doi.org/10.1016/j.bja.2021.11.021
doi: 10.1016/j.bja.2021.11.021 pubmed: 34895716
Deniau B, Rehfeld L, Santos K et al (2020) Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. Eur J Heart Fail 22:290–299. https://doi.org/10.1002/ejhf.1601
doi: 10.1002/ejhf.1601 pubmed: 31472040
Deniau B, Blet A, Santos K et al (2020) Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: a proof of concept study. PLoS ONE 15:e0238039. https://doi.org/10.1371/journal.pone.0238039
doi: 10.1371/journal.pone.0238039 pubmed: 32853284 pmcid: 7451654
Sert NPd, Hurst V, Ahluwalia A et al (2020) The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Plos Biol 18:e3000410. https://doi.org/10.1371/journal.pbio.3000410
doi: 10.1371/journal.pbio.3000410
Osuchowski MF, Ayala A, Bahrami S et al (2018) Minimum quality threshold in pre-clinical sepsis studies (MQTiPSS). Shock 50:377–380. https://doi.org/10.1097/shk.0000000000001212
doi: 10.1097/shk.0000000000001212 pubmed: 30106875 pmcid: 6133201
Carrara M, Herpain A, Baselli G, Ferrario M (2020) Vascular decoupling in septic shock: the combined role of autonomic nervous system, arterial stiffness, and peripheral vascular tone. Front Physiol 11:594. https://doi.org/10.3389/fphys.2020.00594
doi: 10.3389/fphys.2020.00594 pubmed: 32733257 pmcid: 7358433
Carrara M, Niccolò A, Herpain A, Ferrario M (2020) Reducing tachycardia in septic shock patients: do esmolol and ivabradine have a chronotropic effect only? 2020 42nd Annu Int Conf Ieee Eng Medicine Biology Soc Embc 00:382–385. https://doi.org/10.1109/embc44109.2020.9176309
Garcia B, Su F, Dewachter L et al (2022) Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock. Crit Care. https://doi.org/10.1186/s13054-022-04161-3
doi: 10.1186/s13054-022-04161-3 pubmed: 36117167 pmcid: 9482744
Kirkpatrick AW, Roberts DJ et al (2013) Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med 39:1190–1206. https://doi.org/10.1007/s00134-013-2906-z
doi: 10.1007/s00134-013-2906-z pubmed: 23673399 pmcid: 3680657
Khanna A, English SW, Wang XS et al (2017) Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 377:419–430. https://doi.org/10.1056/nejmoa1704154
doi: 10.1056/nejmoa1704154 pubmed: 28528561
Ham KR, Boldt DW, McCurdy MT et al (2019) Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial. Ann Intensive Care 9:63. https://doi.org/10.1186/s13613-019-0536-5
doi: 10.1186/s13613-019-0536-5 pubmed: 31161442 pmcid: 6546778
Orso D, Copetti R (2019) Adrenergic overstimulation a neglected mechanism of sepsis-related cardiomyopathy. Chest 155:647. https://doi.org/10.1016/j.chest.2018.09.032
doi: 10.1016/j.chest.2018.09.032 pubmed: 30846069 pmcid: 6435898
Hollenberg SM, Singer M (2021) Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. https://doi.org/10.1038/s41569-020-00492-2
doi: 10.1038/s41569-020-00492-2 pubmed: 33473203
Lyon AR, Rees PS, Prasad S et al (2008) Stress (Takotsubo) cardiomyopathy—a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Card 5:22–29. https://doi.org/10.1038/ncpcardio1066
doi: 10.1038/ncpcardio1066
See EJ, Clapham C, Liu J et al (2023) A pilot study of angiotensin II as primary vasopressor in critically ill adults with vasodilatory hypotension: The Aramis Study. Shock 59:691–696. https://doi.org/10.1097/shk.0000000000002109
doi: 10.1097/shk.0000000000002109 pubmed: 36930693
Spink J, Cohen J, Evans TJ (1995) The cytokine responsive vascular smooth muscle cell enhancer of inducible nitric oxide synthase activation by nuclear factor-κB (*). J Biol Chem 270:29541–29547. https://doi.org/10.1074/jbc.270.49.29541
doi: 10.1074/jbc.270.49.29541 pubmed: 7493996
Kimmoun A, Ducrocq N, Levy B (2013) Mechanisms of vascular hyporesponsiveness in septic shock. Curr Vasc Pharmacol 11:139–149. https://doi.org/10.2174/1570161111311020004
doi: 10.2174/1570161111311020004 pubmed: 23506493
Garcia B, Su F, Manicone F et al (2023) Angiotensin 1–7 in an experimental septic shock model. Crit Care 27:106. https://doi.org/10.1186/s13054-023-04396-8
doi: 10.1186/s13054-023-04396-8 pubmed: 36915144 pmcid: 10010236
Adachi Y, Saito Y, Kishimoto I et al (2003) Angiotensin II Type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation 107:2406–2408. https://doi.org/10.1161/01.cir.0000072763.98069.b4
doi: 10.1161/01.cir.0000072763.98069.b4 pubmed: 12732609
Carrara M, Ferrario M, Pinto BB, Herpain A (2021) The autonomic nervous system in septic shock and its role as a future therapeutic target: a narrative review. Ann Intensive Care 11:80. https://doi.org/10.1186/s13613-021-00869-7
doi: 10.1186/s13613-021-00869-7 pubmed: 33999297 pmcid: 8128952
Stolk R, van der Pasch E, Naumann F et al (2020) Norepinephrine dysregulates the immune response and compromises host defense during sepsis. Am J Respir Crit Care Med. https://doi.org/10.1164/rccm.202002-0339oc
doi: 10.1164/rccm.202002-0339oc pubmed: 32520577
Picod A, Placier S, Genest M et al (2024) Circulating dipeptidyl peptidase 3 modulates systemic and renal hemodynamics through cleavage of angiotensin peptides. Hypertension. https://doi.org/10.1161/hypertensionaha.123.21913
doi: 10.1161/hypertensionaha.123.21913 pubmed: 38334001
Leisman DE, Privratsky JR, Lehman JR et al (2022) Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis model. Proc Natl Acad Sci 119:e2211370119. https://doi.org/10.1073/pnas.2211370119
doi: 10.1073/pnas.2211370119 pubmed: 35969740 pmcid: 9407661
Teboul J-L, Monnet X, Chemla D, Michard F (2019) Arterial pulse pressure variation with mechanical ventilation. Am J Respir Crit Care Med 199:22–31. https://doi.org/10.1164/rccm.201801-0088ci
doi: 10.1164/rccm.201801-0088ci pubmed: 30138573
Sakr Y, Birri PNR, Kotfis K et al (2017) Higher fluid balance increases the risk of death from sepsis. Crit Care Med 45:386–394. https://doi.org/10.1097/ccm.0000000000002189
doi: 10.1097/ccm.0000000000002189 pubmed: 27922878
Hall A, Busse LW, Ostermann M (2018) Angiotensin in critical care. Crit Care 22:69. https://doi.org/10.1186/s13054-018-1995-z
doi: 10.1186/s13054-018-1995-z pubmed: 29558991 pmcid: 5861652
Wieruszewski PM, Coleman PJ, Levine AR et al (2023) Trajectory of PaO 2 /FiO 2 ratio in shock after angiotensin II. J Intensive Care Med. https://doi.org/10.1177/08850666231174870
doi: 10.1177/08850666231174870 pubmed: 37161301
Leisman DE, Handisides DR, Chawla LS et al (2023) Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock. Ann Intensive Care 13:128. https://doi.org/10.1186/s13613-023-01227-5
doi: 10.1186/s13613-023-01227-5 pubmed: 38103056 pmcid: 10725390
Levy B, Gibot S, Franck P et al (2005) Relation between muscle Na+K+ ATPase activity and raised lactate concentrations in septic shock: a prospective study. Lancet 365:871–875. https://doi.org/10.1016/s0140-6736(05)71045-x
doi: 10.1016/s0140-6736(05)71045-x pubmed: 15752531
Calzavacca P, Evans RG, Bailey M et al (2015) Cortical and medullary tissue perfusion and oxygenation in experimental septic acute kidney injury. Crit Care Med 43:e431–e439. https://doi.org/10.1097/ccm.0000000000001198
doi: 10.1097/ccm.0000000000001198 pubmed: 26181218
Garcia B, Zarbock A, Bellomo R, Legrand M (2023) The role of renin-angiotensin system in sepsis-associated acute kidney injury: mechanisms and therapeutic implications. Curr Opin Crit Care. https://doi.org/10.1097/mcc.0000000000001092
doi: 10.1097/mcc.0000000000001092 pubmed: 37861190
Wan L, Langenberg C, Bellomo R, May CN (2009) Angiotensin II in experimental hyperdynamic sepsis. Crit Care 13:R190. https://doi.org/10.1186/cc8185
doi: 10.1186/cc8185 pubmed: 19948019 pmcid: 2811902
Legrand M, Dupuis C, Simon C et al (2013) Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care 17:R278. https://doi.org/10.1186/cc13133
doi: 10.1186/cc13133 pubmed: 24289206 pmcid: 4056656

Auteurs

Bruno Garcia (B)

Experimental Laboratory of the Department of Intensive Care, Université Libre de Bruxelles (ULB), Brussels, Belgium. br.garcia@icloud.com.
Department of Intensive Care, Centre Hospitalier Universitaire de Lille, Lille, France. br.garcia@icloud.com.

Benoit Ter Schiphorst (B)

Experimental Laboratory of the Department of Intensive Care, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Intensive Care, Centre Hospitalier Universitaire de Lille, Lille, France.

Karine Santos (K)

4TEEN4 Pharmaceuticals GmbH, Hennigsdorf, Germany.

Fuhong Su (F)

Experimental Laboratory of the Department of Intensive Care, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Laurence Dewachter (L)

Laboratory of Physiology and Pharmacology, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Francisco Vasques-Nóvoa (F)

Cardiovascular R&D Center, Faculty of Medicine, University of Porto, Porto, Portugal.

Estela Rocha-Oliveira (E)

Cardiovascular R&D Center, Faculty of Medicine, University of Porto, Porto, Portugal.

Roberto Roncon-Albuquerque (R)

Cardiovascular R&D Center, Faculty of Medicine, University of Porto, Porto, Portugal.

Theo Uba (T)

4TEEN4 Pharmaceuticals GmbH, Hennigsdorf, Germany.

Oliver Hartmann (O)

4TEEN4 Pharmaceuticals GmbH, Hennigsdorf, Germany.

Adrien Picod (A)

Université Paris Cité, UMR-S 942, INSERM, MASCOT, Paris, France.

Feriel Azibani (F)

Université Paris Cité, UMR-S 942, INSERM, MASCOT, Paris, France.

Jacques Callebert (J)

Université Paris Cité, UMR-S 942, INSERM, MASCOT, Paris, France.
Department of Biochemistry, Assistance Publique Hôpitaux de Paris, Hôpital Lariboisière, Paris, France.

Serge Goldman (S)

Department of Nuclear Medicine, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Filippo Annoni (F)

Experimental Laboratory of the Department of Intensive Care, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Raphaël Favory (R)

Department of Intensive Care, Centre Hospitalier Universitaire de Lille, Lille, France.

Jean-Louis Vincent (JL)

Experimental Laboratory of the Department of Intensive Care, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Jacques Creteur (J)

Experimental Laboratory of the Department of Intensive Care, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Fabio Silvio Taccone (FS)

Experimental Laboratory of the Department of Intensive Care, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.

Alexandre Mebazaa (A)

Université Paris Cité, UMR-S 942, INSERM, MASCOT, Paris, France.
Department of Anesthesia, Burn and Critical Care, University Hospitals Saint-Louis-Lariboisière, AP-HP, Paris, France.

Antoine Herpain (A)

Experimental Laboratory of the Department of Intensive Care, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Intensive Care, Saint-Pierre University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Classifications MeSH